Stay updated with breaking news from Delta Alpha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On Wednesday morning, Pfizer and BioNTech released a press release on their vaccine protection against the Omicron variant of COVID-19, which was announced as a "variant of concern" by the
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies
Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection As 80% of epitopes in the spike protein recognized by CD8+ T cells are not ...
Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage), while two doses show significantly reduced neutralization
Investegate announcements from BioNTech SE, Pfizer and BioNTech Provide Update on Omicron Variant